Knee anatomy
Your knee is a complex joint made up of three different bones—the thigh bone (femur), shin bone (tibia), and knee cap (patella)—as well as different types of cartilage, and important ligaments that connect the shin and thigh bones. Cartilage protects the joint and aids in movement. There are two types of cartilage in the knee:
Meniscus:
Two crescent-shaped wedges of cartilage that act as a cushion between the thigh bone and the shin bone in your knee.
Articular Cartilage:
Also known as hyaline cartilage, this durable tissue covers the ends of bones. It provides a smooth and impact-resistant surface to help you during activities such as walking, kneeling, running, and jumping.
Position your mouse over the terms below to view the illustrated definitions.
Click to show Anatomical Terms
Ready to get back to action with CARTICEL? You’re already on the right path.
I'm Ready
Have Questions?
Check out our FAQs for answers—or contact a Carticel Care® Coordinator at 800-453-6948, Option #2, for more detailed information.
Email a question
Indications and Usage
Carticel® (autologous cultured chondrocytes) is an autologous cellular product indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft).
CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown.
CARTICEL is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis.
CARTICEL is not recommended for patients with total meniscectomy unless surgically reconstructed prior to or concurrent with CARTICEL implantation.
Important Safety Information
CARTICEL should not be used in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides or materials of bovine origin.
It should not be used in patients who have previously had cancer in the bones, cartilage, fat or muscle of the treated limb.
Pre-existing conditions, including meniscal tears, joint instability, or malalignment should be assessed and treated prior to or concurrent with CARTICEL implantation.
CARTICEL is not routinely tested for transmissible infectious diseases and may transmit disease to the healthcare provider handling CARTICEL.
Use of CARTICEL in children, patients over age 65, or in joints other than the knee has not yet been assessed.
The occurrence of subsequent surgical procedures (SSPs), primarily arthroscopy, following CARTICEL implantation is common. In the Study of the Treatment of Articular Repair (STAR), forty-nine percent (49%) of patients underwent an SSP on the treated knee, irrespective of their relationship to CARTICEL, during the 4-year follow up. The most common serious adverse events (≥5% of patients), derived from STAR, include arthrofibrosis/joint adhesions, graft overgrowth, chondromalacia or chondrosis, cartilage injury, graft complication, meniscal lesion, graft delamination, and osteoarthritis.
For more information on CARTICEL, please see the Package Insert (PDF).